Founders Capital Management Amgen Inc Transaction History

Founders Capital Management

$164 Million
Q3 2024

A detailed history of Founders Capital Management transactions in Amgen Inc stock. As of the latest transaction made, Founders Capital Management holds 409 shares of AMGN stock, worth $107,640. This represents 0.08% of its overall portfolio holdings.

Number of Shares

409

Previous 409 -0.0%

Holding current value

$107,640

Previous $127,000 3.15%

% of portfolio

0.08%

Previous 0.08%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 10, 2023	SELL	$218.65 - $271.46 $89,209 - $110,755	-408 Reduced 49.94%	409 $109,000
Q3 2021 Oct 12, 2021	BUY	$212.27 - $248.7 $173,424 - $203,187	817 New	817 $174,000
Q4 2019 Jan 24, 2020	SELL	$189.21 - $243.2 $2.22 Million - $2.86 Million	-11,740 Closed	0 $0
Q2 2019 Jul 11, 2019	SELL	$166.7 - $195.41 $8,335 - $9,770	-50 Reduced 0.42%	11,740 $2.16 Million
Q1 2019 Apr 17, 2019	BUY	$180.87 - $203.88 $18,087 - $20,388	100 Added 0.86%	11,790 $2.24 Million
Q4 2018 Jan 14, 2019	SELL	$178.4 - $208.25 $16,056 - $18,742	-90 Reduced 0.76%	11,690 $2.28 Million
Q3 2018 Oct 05, 2018	SELL	$185.29 - $208.89 $2,779 - $3,133	-15 Reduced 0.13%	11,780 $2.44 Million
Q2 2018 Jul 09, 2018	BUY	$166.05 - $186.51 $4,981 - $5,595	30 Added 0.25%	11,795 $2.18 Million
Q1 2018 Apr 09, 2018	BUY	$169.43 - $198.0 $10,165 - $11,880	60 Added 0.51%	11,765 $2.01 Million
Q4 2017 Jan 22, 2018	SELL	$168.79 - $188.59 $118,153 - $132,013	-700 Reduced 5.64%	11,705 $2.04 Million
Q3 2017 Oct 17, 2017	BUY	$167.29 - $191.0 $2.08 Million - $2.37 Million	12,405	12,405 $2.31 Million

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Founders Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Founders Capital Management with notifications on news.

Account

Founders Capital Management Amgen Inc Transaction History